PUBLISHER: GlobalData | PRODUCT CODE: 1827109
PUBLISHER: GlobalData | PRODUCT CODE: 1827109
Age-Related Macular Degeneration: Epidemiology Forecast to 2034
Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye Institution, 2021). A meta-analysis indicated a pooled prevalence of 8.69% for any AMD in adults ages 45-85 years. However, country-specific prevalence can reach 30-40%. Beyond its high prevalence, AMD is linked to severe disability, significantly impacting the quality of life and emotional well-being of affected individuals (Augood et al., 2006; Hassell, 2006; Wong et al., 2014).
In 2024, there were 13,788,126 diagnosed incident cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 3,378,351 diagnosed incident cases, while Germany accounted for the fewest cases with 1,160,172 cases in 2024. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of AMD to 15,349,696 cases in 2034 in the 7MM at an annual growth rate (AGR) of 1.13% during the forecast period.
In 2024, there were 93,262,936 total prevalent cases of AMD in men and women combined, ages 50 years and older, in the 7MM. The US accounted for the majority of these cases with 23,514,756 total prevalent cases, while Germany accounted for the fewest cases with 7,799,623 cases in 2024. GlobalData epidemiologists forecast an increase in the total prevalent cases of AMD to 103,016,570 cases in 2034 in the 7MM at an AGR of 1.05% during the forecast period.
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides a 10-year epidemiological forecast of the diagnosed incident cases (newly diagnosed patients), total prevalent cases (including both diagnosed and undiagnosed), and diagnosed prevalent cases of AMD. In this analysis, AMD cases are segmented into early AMD and late AMD, with late AMD further segmented into late dry AMD and wet AMD subtypes.
- In this report, each segment is broken down by sex and age (50-59 years, 60-69 years, 70-79 years, and 80 years and older). The total prevalent cases and diagnosed prevalent cases of late dry AMD and wet AMD were segmented for both sexes and ages 50 years and older.
- The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. Additionally, in cases of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
Reasons to Buy
- The Age-related macular degeneration (AMD) epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
Table of Contents
Table of Contents
1 Age-Related Macular Degeneration: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of AMD
- 2.4.4 Forecast assumptions and methods: total prevalent cases of AMD
- 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
- 2.5 Epidemiological forecast for AMD (2024-34)
- 2.5.1 Diagnosed incident cases of AMD
- 2.5.2 Age-specific diagnosed incident cases of AMD
- 2.5.3 Sex-specific diagnosed incident cases of AMD
- 2.5.4 Diagnosed incident cases of early AMD
- 2.5.5 Diagnosed incident cases of late AMD
- 2.5.6 Diagnosed incident cases of late dry AMD
- 2.5.7 Diagnosed incident cases of wet AMD
- 2.5.8 Total prevalent cases of AMD
- 2.5.9 Age-specific total prevalent cases of AMD
- 2.5.10 Sex-specific total prevalent cases of AMD
- 2.5.11 Total prevalent cases of early AMD
- 2.5.12 Total prevalent cases of late AMD
- 2.5.13 Total prevalent cases of late dry AMD
- 2.5.14 Total prevalent cases of wet AMD
- 2.5.15 Diagnosed prevalent cases of AMD
- 2.5.16 Age-specific diagnosed prevalent cases of AMD
- 2.5.17 Sex-specific diagnosed prevalent cases of AMD
- 2.5.18 Diagnosed prevalent cases of early AMD
- 2.5.19 Diagnosed prevalent cases of late AMD
- 2.5.20 Diagnosed prevalent cases of late dry AMD
- 2.5.21 Diagnosed prevalent cases of wet AMD
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Limitations of the analysis
- 2.6.3 Strengths of the analysis
3 Appendix
- 3.1 Bibliography
- 3.2 Primary research - prescriber survey
- 3.3 About the authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Intelligence and Epidemiology
- 3.3.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About GlobalData
List of Table
List of Tables
- Table 1: Summary of changes to data types and countries
- Table 2: Summary of updated data types
- Table 3: Risk factors and comorbid conditions associated with AMD
- Table 4: High-prescribing physicians (KOL and non-KOLs) surveyed, by country
List of Figure
List of Figures
- Figure 1: 7MM, diagnosed incident cases of AMD, both sexes, N, ages >=50 years, 2024 and 2034
- Figure 2: 7MM, total prevalent cases of AMD, both sexes, N, ages >=50 years, 2024 and 2034
- Figure 3: 7MM, diagnosed prevalent cases of AMD, both sexes, N, ages >=50 years, 2024 and 2034
- Figure 4: 7MM, diagnosed incidence of AMD, both sexes, ages >=50 years, cases per 100,000 population, 2024
- Figure 5: 7MM, total prevalence of AMD, both sexes, ages >=50 years, %, 2024
- Figure 6: 7MM, diagnosed prevalence of AMD, both sexes, ages >=50 years, 2024
- Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
- Figure 8: 7MM, sources used and not used to forecast the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
- Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of AMD, early AMD, late AMD, late dry AMD, and wet AMD
- Figure 10: 7MM, diagnosed incident cases of AMD, N, both sexes, ages >=50 years, 2024
- Figure 11: 7MM, age-specific diagnosed incident cases of AMD, both sexes, N, ages >=50 years, 2024
- Figure 12: 7MM, sex-specific diagnosed incident cases of AMD, N, ages >=50 years, 2024
- Figure 13: 7MM, diagnosed incident cases of early AMD, N, both sexes, ages >=50 years, 2024
- Figure 14: 7MM, diagnosed incident cases of late AMD, N, both sexes, ages >=50 years, 2024
- Figure 15: 7MM, diagnosed incident cases of late dry AMD, N, both sexes, ages >=50 years, 2024
- Figure 16: 7MM, diagnosed incident cases of wet AMD, N, both sexes, ages >=50 years, 2024
- Figure 17: 7MM, total prevalent cases of AMD, both sexes, ages >=50 years, N, 2024
- Figure 18: 7MM, age-specific total prevalent cases of AMD, both sexes, N, ages >=50 years, 2024
- Figure 19: 7MM, sex-specific total prevalent cases of AMD, N, ages >=50 years, 2024
- Figure 20: 7MM, total prevalent cases of early AMD, both sexes, ages >=50 years, N, 2024
- Figure 21: 7MM, total prevalent cases of late AMD, both sexes, ages >=50 years, N, 2024
- Figure 22: 7MM, total prevalent cases of late dry AMD, both sexes, ages >=50 years, N, 2024
- Figure 23: 7MM, total prevalent cases of wet AMD, both sexes, ages >=50 years, N, 2024
- Figure 24: 7MM, diagnosed prevalent cases of AMD, both sexes, ages >=50 years, N, 2024
- Figure 25: 7MM, age-specific diagnosed prevalent cases of AMD, both sexes, N, ages >=50 years, 2024
- Figure 26: 7MM, sex-specific diagnosed prevalent cases of AMD, N, ages >=50 years, 2024
- Figure 27: 7MM, diagnosed prevalent cases of early AMD, both sexes, ages >=50 years, N, 2024
- Figure 28: 7MM, diagnosed prevalent cases of late AMD, both sexes, ages >=50 years, N, 2024
- Figure 29: 7MM, diagnosed prevalent cases of late dry AMD, both sexes, ages >=50 years, N, 2024
- Figure 30: 7MM, diagnosed prevalent cases of wet AMD, both sexes, ages >=50 years, N, 2024
